We explored the potential of MIF polymorphism as genetic risk or protective alleles for depression, as well as the utility of peripheral transcriptomic and proteomic MIF levels as a biomarker for MDD and predictor of treatment response, to guide selection for the personalized treatment for patients with MDD. The gene discussed is MIF; the disease is depressive disorder.